• Sterling, Charles R (PI)
  • Riggs, Michael W (PI)
  • Cama, Vitialiano (PI)
  • Enriquez, F. Javier (PI)
  • Perryman, Lance (PI)

    Project: Research project

    Grant Details


    Cryptosporidium parvum may produce persistent diarrheal illness in AIDS
    patients. The number of infected AIDS patients is likely to be
    underreported. Unfortunately, chemotherapeutic attempts at treatment have
    so far failed. Recent studies have provided evidence that treatment with
    hyperimmune antibody preparations may significantly reduce the severity of
    disease. Following through on this idea, we plan to focus on monoclonal
    antibody (Mab) approach to prophylaxis and treatment because these regent
    have uniformity, can be produced in unlimited quantity, can identify
    important parasite antigens and, therefore, may open up alternative
    treatment strategies, and can be exhaustively tested using appropriate
    animal model systems. Since it is likely that these Mabs will be most effective if a maximum
    number of life cycle stages can be neutralized, we will focus on producing
    neutralizing MAbs against the sporozoite merozoite and sexual stages of an
    Ioqa isolate of Cryptosporidium to be provided to all program projects and
    core facilities. the activity of these MAbs will be tested, either alone
    or in combination, using immunocompetent neonatal mouse models of
    neutralization or prophylaxis. In addition, we will test the activity of
    these MAbs by using an immunocompetent neonatal mouse model of treatment
    immunocompromised mouse models of prophylaxis and treatment, and by using
    improved upon or newly developed in vitro cultures to study stage-specific
    neutralization. Each program project will characterize and isolate
    relevant stage-specific antigens and will make them available for
    production of bovine-murine and human MAbs as an alternative treatment
    strategy for controlling this infection in AIDS patients. Because some of
    these antigens may be difficult to identify or produce, we will rely on the
    construction of a cDNA and genomic library and use of appropriate library
    expression vectors. Monoclonal antibodies showing prophylactic and
    treatment efficacy and which warrant clinical testing eventually will be
    produced in quantity.
    Effective start/end date7/1/905/31/99


    • National Institutes of Health


    • Medicine(all)
    • Immunology and Microbiology(all)


    Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.